ICON Central Laboratories Launches iSite Portal for Investigator Sites
ICON plc
(NASDAQ: ICLR; ISIN:IE0005711209), a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries, today announced the launch of
iSite
, a secure web-based portal that drives efficiency by providing investigators 24-hour access to study-specific laboratory information from
ICON Central Laboratories
.
iSite
is an easy-to-use portal that allows investigators and other site personnel to access electronic laboratory reports for their active studies at any time. It includes user-friendly navigation, filtering and report management and provides investigators customised views of reports by study, site, subject or visit date. iSite also includes email alert functionality which notifies investigators when new reports become available.
“We are continuously looking to introduce innovative technology solutions that drive efficiency and improve performance,” commented
Tom O’Leary
, President, ICON Central Laboratories. “iSite provides investigators a much needed solution for accessing important study-specific information in the most rapid, secure and convenient way possible.”
A future release of iSite is in development and will provide sites with study-specific performance metrics and additional tools such as customised electronic laboratory manuals which will be created by ICON’s
Firecrest™ technology
. ICON’s Firecrest delivers an innovative suite of training and study management tools which can significantly improve the compliance, consistency and execution of study-related activities at investigator sites.
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
FDA-Approved Gene Therapy Beqvez Shows Sustained Efficacy, Safety in Long-Term Hemophilia B Trial
April 17th 2025Beqvez (fidanacogene elaparvovec), an FDA-approved one-time gene therapy for hemophilia B, demonstrated sustained factor IX expression, low bleeding rates, and a favorable safety profile over long-term follow-up.
